Don’t take it personally mate. It needed to be short & sweet, the regulatory approval from the Italian Ministry of Health should be though within a month & the up-scaling of test kits & reagent manufacture needs to be ready to meet demand. When Daniel noticed some time ago PIQ were employing a Manufacturing Manager, that was a massive clue things were about to happen.
@Eqz a very good summary you have put together mate, thank you!
Yes please hurry up with the Endometriosis non-invasive screening (as opposed to a general anaesthetic and laparoscopy). I have suffered with this all my adult life and I would not hesitate to get my daughter tested albeit even on a clinical trial, because like most, it took 16 years for my diagnosis, after being told by a few GPs that my debilitating symptoms were “normal” and to basically “just deal with it” which I do. I’ve had multiple miscarriages but have 2 healthy children, so I’m one of the lucky ones to have 2 “miracles”.
There is far more awareness now Medically (1 in 9 women & young girls suffer and girls are getting their period as young as 8 years old). To me that is just heartbreaking, and you don’t want to see the next generation suffer (our children) in what is a chronic disease that can result in infertility amongst other things. Early diagnosis is essential. This has the potential to be just as big as PromarkerD in an unmet clinical need.
Menstruation is a monthly fact of life, it is seen as “unclean” in some cultures and is “secret women’s business” in ours. In days gone by women who complained to their GP were labelled as “neurotic” and prescribed highly addictive drugs (benzodiazepines and opioids) So no wonder a lot of women suffer in silence and that should not be the case.
Just one thing I’d like to add to your comments on PromarkerD for DKD @Eqz and that’s the need for this test more than ever with COVID-19 and lockdowns.
Diabetes and CKD are known massive risk factors for mortality from COVID-19 and unfortunately patients are not receiving the screening and monitoring to meet standard of care, not everything can be done over telehealth. We are seeing this in Australia as well, so I can only imagine the scope of the problem in the UK, Europe & the USA.
It’s already a massive issue and has been addressed in both EU and the USA recently with new guidelines for screening for DKD, but I think what we will see in the coming months and years will be a huge blowout in DKD and global health budgets.
A simple non-invasive blood test can actually change the course of disease with new treatments available now to prevent or slow decline in renal function. This is a big difference between now & 2017-2018 when we both invested here (looking at unmet clinical needs). There is actually now something more than lifestyle modification, strict glycaemic control and treatment with ARBs Or ACE inhibitors to control BP. SGLT2s approved both in the USA & EU. More to come.
Just looking at the bigger picture here.
GLTAH
PIQ Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)